Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations

American Journal of Public Health

Volumn 89, Issue 3, 1999, Pages 364-368

  Jafari, Hamid S ^a,b   Adams, William G ^a   Robinson, Katherine A ^a   Plikaytis, Brian D ^a   Wenger, Jay D ^a,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROWDING; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SINGLE PARENT; SOCIOECONOMICS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033024601     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.89.3.364     Document Type: Article

References (31)

1. Cochi SL, Broome CV, Hightower AW. Immunization of U.S. children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 1985;253:521-529.
2. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-226.
3. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hibl in children immunized with an Hib conjugate vaccine. J Infect Dis. 1991;164:982-986.
4. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61080 children. Pediatr Infect Dis J. 1991;10:97-104.
5. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324:1767-1772.
6. Wenger JD, Pierce R, Deaver KA, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet. 1991;338:395-398.
7. Vadheim CM, Greenberg DP, Eriksen E, et al. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study. Pediatr Infect Dis J. 1994;13:274-280.
8. Istre GR, Conner JS, Broome CV, Hightower A, Hopkins RS. Risk factors for primary invasive Haemophilus influenzae disease: increased risk from day care attendance and school-aged household members. J Pediatr. 1985;106:190-195.
9. Cochi SL, Fleming DW, Hightower AW, et al. Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr. 1986;108:887-896.
10. Black SR, Shinefield HR, The Kaiser Permanente Pediatric Vaccine Study Group. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine of a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. Pediatr Infect Dis J. 1992;11:610-613.
11. Murphy TV, White KE, Pastor P, et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA. 1993;269:246-248.
12. Broadhurst LE, Erickson RL, Kelley PW. Decreases in invasive Haemophilus influenzae diseases in U.S. army children, 1984 through 1991. JAMA. 1993;269:227-231.
13. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-1995. MMWR Morb Mortal Wkly Rep. 1996;45:901-906.
14. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis. 1998;4:229-237.
15. Haemophilus influenzae infections. In: Peter G, ed. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1994:203-216.
16. Centers for Disease Control. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. MMWR Morb Mortal Wkly Rep. 1993;42(RR-13):1-15.
17. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices update: report of PedvaxHIB lots with questionable immunogenicity. MMWR Morb Mortal Wkly Rep. 1992;41:878-879.
18. Murphy TV, Pastor PN, Medley FB, Osterholm MT, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr. 1993;122:517-523.
19. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J. 1993;12:589-593.
20. Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171:93-98.
21. Bates AS, Fitzgerald JF, Dittus RS, Wolinsky FD. Risk factors for underimmunization in poor urban infants. JAMA. 1994;272:1105-1110.
22. Bobo JK, Gale JL, Thapa PB, Wassilak SGF. Risk factors for delayed immunization in a random sample of 1163 children from Oregon and Washington. Pediatrics. 1993;91:308-314.
23. Hueston WJ, Mainous AG III, Palmer C. Delays in childhood immunizations in public and private settings. Arch Pediatr Adolesc Med. 1994;148:470-473.
24. Centers for Disease Control and Prevention. Vaccination coverage of 2-year-old children - United States. 1991-1992. MMWR Morb Mortal Wkly Rep. 1994;42:985-988.
25. Centers for Disease Control and Prevention. Vaccination coverage levels among children aged 19-35 months - United States. April-June, 1994. MMWR Morb Mortal Wkly Rep. 1995;44:396-398.
26. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19 35 months - United States, April 1994-March 1995. MMWR Morb Mortal Wkly Rep. 1996;45:145-150.
27. Scheifele D, Gold R, Marchessault V, Duclos P. Failures after immunization with Haemophilus influenzae type b vaccines - 1991-1995. Can Commun Dis Rep. 1996;22:17-20, 23.
28. O'Brien E, Kempe A. Haemophilus influenzae type b vaccination coverage in the Australian capital territory for children aged nine months and two years. Comm Dis Intell. 1996;20: 256-258.
29. Jonsdottir KE, Hansen H, Arnorsson VH, et al. Immunization against Haemophilus influenzae type b in Iceland: results after six years use of PRP-D (Pro-Hibit). Iceland Med J. 1996;82: 32-38.
30. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet. 1992;340:592-594.
31. Pan American Health Organization. Impact of Uruguay's introduction of the Haemophilus influenzae type b (Hib) vaccine. EPI Newsletter. 1996;18:6.